Seventy-eight-year-old Joe Walsh, of Quincy, is in a unique position. He is the first patient to have permission from the U.S. Food and Drug Administration to try a nasal spray for moderate ...

Just because you can buy a medication over the counter doesn’t mean it’s always safe. Here’s how you should really be using ...

Almost 100,000 bottles of nasal spray were recalled for a "microbial failure" that led to multiple complaints from customers.

STATEN ISLAND, N.Y. — The U.S. Food and Drug Administration (FDA) has announced a recall of 89,312 bottles of a popular nasal ...

Retired electrician Joe Walsh in December became the first Alzheimer’s patient to try a nasal spray used to treat other ...

The drug is designed to reduce inflammation in the brain and has been used on MS, cancer and migraine headaches.

The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.

There’s another recall to be aware of right now, and it involves nose spray. NeilMed Pharmaceuticals Inc., the manufacturer ...

Joe Walsh is now testing a new treatment using a nasal spray, the medication inside is called Foralumab. He is the first patient with Alzheimer's to try it. The Walsh family is hopeful. Foralumab is ...

The Food and Drug Administration (FDA) has expanded its approval of a ketamine-derived nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.

The FDA’s latest approval of the nasal spray Spravato (esketamine) CIII marks a major shift in how major depressive disorder is managed, allowing people who have tried at least two oral ...